Role of epigenetics in Rett syndrome

Epigenomics

Volumn 5, Issue 5, 2013, Pages 583-592

  Kubota, Takeo ^a   Miyake, Kunio ^a   Hirasawa, Takae ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

DNA methylation; epigenetics; iPSC; MeCP2; neurodevelopmental disease; Rett syndrome

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; BRAIN DERIVED NEUROTROPHIC FACTOR; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 3B; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE 2; HISTONE H3; METHYL CPG BINDING PROTEIN; METHYL CPG BINDING PROTEIN 2; RNA BINDING PROTEIN; RNA BINDING PROTEIN YB1; TRICHOSTATIN A; UNCLASSIFIED DRUG; VESICULAR GLUTAMATE TRANSPORTER 1;

ASTROCYTE; BONE MARROW; CHROMATIN ASSEMBLY AND DISASSEMBLY; DEVELOPMENTAL DISORDER; DNA METHYLATION; EMBRYO DEVELOPMENT; EPIGENETICS; FACILITATION; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; HISTONE ACETYLATION; HISTONE MODIFICATION; HISTOPATHOLOGY; HUMAN; LONG TERM POTENTIATION; MICROARRAY ANALYSIS; MICROGLIA; MICROGLIAL CELL CULTURE; NERVE CELL; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; NULL ALLELE; PAIRED PULSE FACILITATION; POINT MUTATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RETT SYNDROME; REVIEW; X CHROMOSOME INACTIVATION; ANIMAL; GENETIC EPIGENESIS; GENETICS; METABOLISM; MUTATION;

ANIMALS; EPIGENESIS, GENETIC; METHYL-CPG-BINDING PROTEIN 2; MUTATION; NEURONS; RETT SYNDROME;

EID: 84885014695     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.13.54     Document Type: Review

References (92)

1. Hagberg B, Aicardi J, Dias K, Ramos O. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases. Ann. Neurol. 14, 471-479 (1983).
2. Bienvenu T, Philippe C, De Roux N et al. The incidence of Rett syndrome in France. Pediatr. Neurol. 34, 372-375 (2006).
3. Webb T, Clarke A, Hanefeld F, Pereira JL, Rosenbloom L, Woods CG. Linkage analysis in Rett syndrome families suggests that there may be a critical region at Xq28. J. Med. Genet. 35, 997-1003 (1998).
4. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23, 185-188 (1999).
5. Kubota T, Saitoh S, Matsumoto T et al. Excess functional copy of allele at chromosomal region 11p15 may cause Wiedemann-Beckwith (EMG) syndrome. Am. J. Med. Genet. 49, 378-383 (1994).
6. Kubota T, Das S, Christian SL, Baylin SB, Herman JG, Ledbetter DH. Methylation-specific PCR simplifies imprinting analysis. Nat. Genet. 16, 16-17 (1997).
7. Kubota T, Wakui K, Nakamura T et al. The proportion of cells with functional X disomy is associated with the severity of mental retardation in mosaic ring X Turner syndrome females. Cytogenet. Genome Res. 99, 276-284 (2002).
8. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99, 247-257 (1999).
9. Xu GL, Bestor TH, Bourc'his D et al. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 402, 187-191 (1999).
10. Shirohzu H, Kubota T, Kumazawa A et al. Three novel DNMT3B mutations in Japanese patients with ICF syndrome. Am. J. Med. Genet. 112, 31-37 (2002).
11. Chunshu Y, Endoh K, Soutome M, Kawamura R, Kubota T. A patient with classic Rett syndrome with a novel mutation in MECP2 exon 1. Clin. Genet. 70, 530-531 (2006).
12. Monteggia LM, Kavalali ET. Rett syndrome and the impact of MeCP2 associated transcriptional mechanisms on neurotransmission. Biol. Psychiatry 65, 204-210 (2009).
13. Takeshita E, Saito Y, Nakagawa E et al. Late-onset mental deterioration and fluctuating dystonia in a female patient with a truncating MECP2 mutation. J. Neurol. Sci. 308, 168-172 (2011).
14. Augenstein K, Lane JB, Horton A, Schanen C, Percy AK. Variable phenotypic expression of a MECP2 mutation in a family. J. Neurodev. Disord. 1, 313 (2009).
15. Schanen NC, Dahle EJ, Capozzoli F, Holm VA, Zoghbi HY, Francke U. A new Rett syndrome family consistent with X-linked inheritance expands the X chromosome exclusion map. Am. J. Hum. Genet. 61, 634-641 (1997).
16. Nan X, Campoy FJ, Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88, 471-481 (1997).
17. Kudo S. Methyl-CpG-binding protein MeCP2 represses Sp1-activated transcription of the human leukosialin gene when the promoter is methylated. Mol. Cell. Biol. 18, 5492-5499 (1998).
18. Hendrich B, Bird A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol. Cell. Biol. 18, 6538-6547 (1998).
19. Nan X, Bird A. The biological functions of the methyl-CpG-binding protein MeCP2 and its implication in Rett syndrome. Brain Dev. 23(Suppl. 1), S32-S37 (2001).
20. Wolffe AP. Histone deacetylase: a regulator of transcription. Science 272, 371-372 (1996).
21. Jones PL, Veenstra GJ, Wade PA et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 19, 187-191 (1998).
22. Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J. Biol. Chem. 278, 4035- 4040 (2003).
23. Guy J, Hendrich B, Holmes M, Martin JE, Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat. Genet. 27, 322-326 (2001).
24. Chen RZ, Akbarian S, Tudor M, Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat. Genet. 27, 327-331 (2001).
25. Collins AL, Levenson JM, Vilaythong AP et al. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum. Mol. Genet. 13, 2679-2689 (2004).
26. Van Esch H, Bauters M, Ignatius J et al. Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am. J. Hum. Genet. 77, 442-453 (2005).
27. Chao HT, Zoghbi HY, Rosenmund C. MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number. Neuron 56, 58-65 (2007).
28. Yasui DH, Peddada S, Bieda MC et al. Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes. Proc. Natl Acad. Sci. USA 104, 19416-19421 (2007).
29. Chahrour M, Jung SY, Shaw C et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320, 1224-1229 (2008).
30. Mellén M, Ayata P, Dewell S, Kriaucionis S, Heintz N. MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell 151, 1417-1430 (2012).
31. Gonzales ML, Adams S, Dunaway KW, LaSalle JM. Phosphorylation of distinct sites in MeCP2 modifies cofactor associations and the dynamics of transcriptional regulation. Mol. Cell. Biol. 32, 2894-2903 (2012).
32. Lyst MJ, Ekiert R, Ebert DH et al. Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor. Nat. Neurosci. 16, 898-902 (2013).
33. Ebert DH, Gabel HW, Robinson ND et al. Activity-dependent phosphorylation of MeCP2 threonine 308 regulates interaction with NCoR. Nature 499, 341-345 (2013).
34. Young JI, Hong EP, Castle JC et al. Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc. Natl Acad. Sci. USA 102, 17551-17558 (2005).
35. Ballestar E, Yusufzai TM, Wolffe AP. Effects of Rett syndrome mutations of the methyl-CpG binding domain of the transcriptional repressor MeCP2 on selectivity for association with methylated DNA. Biochemistry 39, 7100-7106 (2000).
36. Adkins NL, Georgel PT. MeCP2: structure and function. Biochem. Cell Biol. 89, 1-11 (2011).
37. Goffin D, Allen M, Zhang L et al. Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responses. Nat. Neurosci. 15, 274-283 (2011).
38. Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY. Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. Hum. Mol. Genet. 11, 115-124 (2002).
39. Nagai K, Miyake K, Kubota T. A transcriptional repressor MeCP2 causing Rett syndrome is expressed in embryonic non-neuronal cells and controls their growth. Brain Res. Dev. Brain Res. 157, 103-106 (2005).
40. Ballas N, Lioy DT, Grunseich C, Mandel G. Non-cell autonomous influence of MeCP2- deficient glia on neuronal dendritic morphology. Nat. Neurosci. 12, 311-317 (2009).
41. Maezawa I, Swanberg S, Harvey D, LaSalle JM, Jin LW. Rett syndrome astrocytes are abnormal and spread MeCP2 deficiency through gap junctions. J. Neurosci. 29, 5051-5061 (2009).
42. Lioy DT, Garg SK, Monaghan CE et al. A role for glia in the progression of Rett's syndrome. Nature 475, 497-500 (2011).
43. Derecki NC, Cronk JC, Lu Z et al. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 484, 105-109 (2012).
44. Derecki NC, Cronk JC, Kipnis J. The role of microglia in brain maintenance: implications for Rett syndrome. Trends Immunol. 34, 144-150 (2013).
45. Tudor M, Akbarian S, Chen RZ, Jaenisch R. Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain. Proc. Natl Acad. Sci. USA 99, 15536-15341 (2002).
46. Chen WG, Chang Q, Lin Y et al. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 302, 885-889 (2003).
47. Martinowich K, Hattori D, Wu H, Fouse S, He F, Hu Y. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 302, 890-893 (2003).
48. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 109, 143-148 (2002).
49. Thompson Ray M, Weickert CS, Wyatt E, Webster MJ. Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J. Psychiatry Neurosci. 36, 195-203 (2011).
50. Horike S, Cai S, Miyano M, Cheng JF, Kohwi-Shigematsu T. Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome. Nat. Genet. 37, 31-40 (2005).
51. Peddada S, Yasui DH, LaSalle JM. Inhibitors of differentiation (ID1, ID2, ID3 and ID4) genes are neuronal targets of MeCP2 that are elevated in Rett syndrome. Hum. Mol. Genet. 15, 2003-2014 (2006).
52. McGill BE, Bundle SF, Yaylaoglu MB, Carson JP, Thaller C, Zoghbi HY. Enhanced anxiety and stress-induced corticosterone release are associated with increased Crh expression in a mouse model of Rett syndrome. Proc. Natl Acad. Sci. USA 103, 18267-18272 (2006).
53. Itoh M, Ide S, Takashima S et al. Methyl CpG-binding protein 2 (a mutation of which causes Rett syndrome) directly regulates insulin-like growth factor binding protein 3 in mouse and human brains. J. Neuropathol. Exp. Neurol. 66, 117-123 (2007).
54. Carouge D, Host L, Aunis D, Zwiller J, Anglard P. CDKL5 is a brain MeCP2 target gene regulated by DNA methylation. Neurobiol. Dis. 38, 414-424 (2010).
55. Miyake K, Hirasawa T, Soutome M et al. The protocadherins, PCDHB1 and PCDH7, are regulated by MeCP2 in neuronal cells and brain tissues. implication for pathogenesis of Rett syndrome. BMC Neurosci. 12, 81 (2011).
56. Chao HT, Zoghbi HY, Rosenmund C. MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number. Neuron 56, 58-65 (2007).
57. Kaufmann WE, Jarrar MH, Wang JS et al. Histone modifications in Rett syndrome lymphocytes: a preliminary evaluation. Brain Dev. 27, 331-339 (2005).
58. Lilja T, Wallenborg K, Björkman K et al. Novel alterations in the epigenetic signature of MeCP2-targeted promoters in lymphocytes of Rett syndrome patients. Epigenetics 8, 246-251 (2013).
59. Vecsler M, Simon AJ, Amariglio N, Rechavi G, Gak E. MeCP2 deficiency downregulates specific nuclear proteins that could be partially recovered by valproic acid in vitro. Epigenetics 5, 61-67 (2010).
60. Skene PJ, Illingworth RS, Webb S et al. Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol. Cell 37, 457-468 (2010).
61. Kondo M, Gray LJ, Pelka GJ, Christodoulou J, Tam PP, Hannan AJ. Environmental enrichment ameliorates a motor coordination deficit in a mouse model of Rett syndrome - Mecp2 gene dosage effects and BDNF expression. Eur. J. Neurosci. 27, 3342-3350 (2008).
62. Lonetti G, Angelucci A, Morando L, Boggio EM, Giustetto M, Pizzorusso T. Early environmental enrichment moderates the behavioral and synaptic phenotype of MeCP2 null mice. Biol. Psychiatry 67, 657-665 (2010).
63. Nag N, Moriuchi JM, Peitzman CG, Ward BC, Kolodny NH, Berger-Sweeney JE. Environmental enrichment alters locomotor behaviour and ventricular volume in Mecp2 1lox mice. Behav. Brain Res. 196, 44-48 (2009).
64. Kerr B, Silva PA, Walz K, Young JI. Unconventional transcriptional response to environmental enrichment in a mouse model of Rett syndrome. PLoS One 5, e11534 (2010).
65. Burdge GC, Lillycrop KA, Phillips ES, Slater- Jefferies JL, Jackson AA, Hanson MA. Folic acid supplementation during the juvenile-pubertal period in rats modifies the phenotype and epigenotype induced by prenatal nutrition. J. Nutr. 139, 1054-1060 (2009).
66. Rimland B. Controversies in the treatment of autistic children: vitamin and drug therapy. J. Child Neurol. 3(Suppl.), S68-S72 (1988).
67. James SJ, Cutler P, Melnyk S et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am. J. Clin. Nutr. 80, 1611-1617 (2004).
68. Moretti P, Sahoo T, Hyland K et al. Cerebral folate deficiency with developmental delay, autism, and response to folinic acid. Neurology 64, 1088-1090 (2005).
69. Glaze DG, Percy AK, Motil KJ et al. A study of the treatment of Rett syndrome with folate and betaine. J. Child Neurol. 24, 551-556 (2009).
70. Weaver IC, Cervoni N, Champagne FA et al. Epigenetic programming by maternal behavior. Nat. Neurosci. 7, 847-854 (2004).
71. Lillycrop KA, Phillips ES, Jackson AA, Hanson MA, Burdge GC. Dietary protein restriction of pregnant rats induces and folic acid supplementation prevents epigenetic modification of hepatic gene expression in the offspring. J. Nutr. 135, 382-386 (2005).
72. Kucharski R, Maleszka J, Foret S, Maleszka R. Nutritional control of reproductive status in honeybees via DNA methylation. Science 319, 1827-1830 (2008).
73. Lillycrop KA, Slater-Jefferies JL, Hanson MA, Godfrey KM, Jackson AA, Burdge GC. Induction of altered epigenetic regulation of the hepatic glucocorticoid receptor in the offspring of rats fed a protein-restricted diet during pregnancy suggests that reduced DNA methyltransferase-1 expression is involved in impaired DNA methylation and changes in histone modifications. Br. J. Nutr. 97, 1064-1073 (2007).
74. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat. Neurosci. 9, 519-525 (2006).
75. Jessberger S, Nakashima K, Clemenson GD Jr et al. Epigenetic modulation of seizure-induced neurogenesis and cognitive decline. J. Neurosci. 27, 5967-5975 (2007).
76. Dong E, Nelson M, Grayson DR, Costa E, Guidotti A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc. Natl Acad. Sci. USA 105, 13614-13619 (2008).
77. Ma DK, Jang MH, Guo JU et al. Neuronal activity-induced Gadd45b promotes epigenetic DNA demethylation and adult neurogenesis. Science 323, 1074-1077 (2009).
78. Lim D, Bowdin SC, Tee L. Clinical and molecular genetic features of Beckwith-Wiedemann syndrome associated with assisted reproductive technologies. Hum. Reprod. 24, 741-747 (2009).
79. Bliek J, Alders M, Maas SM et al. Lessons from BWS twins: complex maternal and paternal hypomethylation and a common source of haematopoietic stem cells. Eur. J. Hum. Genet. 17, 1625-1634 (2009).
80. Fraga MF, Ballestar E, Paz MF et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl Acad. Sci. USA 102, 10604-10609 (2005).
81. Miyake K, Yang C, Minakuchi Y et al. Genomic, epigenomic, expression comparison of monozygotic twins discordant for Rett syndrome. PLoS One 8, e66729 (2013).
82. Hotta A, Cheung AY, Farra N et al. Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency. Nat. Methods 6, 370-376 (2009).
83. Marchetto MC, Carromeu C, Acab A et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 143, 527-539 (2010).
84. Farra N, Zhang WB, Pasceri P, Eubanks JH, Salter MW, Ellis J. Rett syndrome induced pluripotent stem cell-derived neurons reveal novel neurophysiological alterations. Mol. Psychiatry 17, 1261-1271 (2012).
85. Muotri AR, Marchetto MC, Coufal NG et al. L1 retrotransposition in neurons is modulated by MeCP2. Nature 468, 443-446 (2010).
86. Luikenhuis S, Giacometti E, Beard CF, Jaenisch R. Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice. Proc. Natl Acad. Sci. USA 101, 6033-6038 (2004).
87. Guy J, Gan J, Selfridge J, Cobb S, Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science 315, 1143-1147 (2007).
88. Cheung AY, Horvath LM, Carrel L, Ellis J. X-chromosome inactivation in Rett syndrome human induced pluripotent stem cells. Front. Psychiatry 3, 24 (2012).
89. Tchieu J, Kuoy E, Chin MH et al. Female human iPSCs retain an inactive X chromosome. Cell Stem Cell 7, 329-342 (2010).
90. Ballas N, Lioy DT, Grunseich C, Mandel G. Non-cell autonomous influence of MeCP2- deficient glia on neuronal dendritic morphology. Nat. Neurosci. 12, 311-317 (2009).
91. Kishi N, Macklis JD. MeCP2 functions largely cell-autonomously, but also non-cell-autonomously, in neuronal maturation and dendritic arborization of cortical pyramidal neurons. Exp. Neurol. 222, 51-58 (2010).
92. Christodoulou J, Ho G. GeneReview: MECP2-related disorders. www.ncbi.nlm.nih.gov/books/NBK1497/